Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Chandra Bhagat PharmaBOM:542934 +4.98%65 Gross Margin % is 16.64% as of Mar. 2026, which is 17% above its 10-year median of 14.23. GuruFocus rates BOM:542934 with a GF Score™ of 65/100 and a GF Value™ of ₹70.19 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 116 Medical Distribution companies, Chandra Bhagat Pharma ranks better than 56.9% on this metric.
BOM:542934's Gross Margin % is ranked better than 56.9% of 116
companies
in the Medical Distribution industry
Industry Median: 14.9
vs BOM:542934: 19.53
Chandra Bhagat Pharma had a gross margin of 16.64% for the quarter that ended in Mar. 2026 => No sustainable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Chandra Bhagat Pharma was 4.00% per year.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Chandra Bhagat Pharma had a gross margin of 16.64% for the quarter that ended in Mar. 2026 => No sustainable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Chandra Bhagat Pharma Gross Margin % Related Terms
Chandra Bhagat Pharma Gross Margin % Historical Data
* Premium members only.
The historical data trend for Chandra Bhagat Pharma's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:542934 vs MCK, CAH, COR: Gross Margin % Comparison
For the Medical Distribution subindustry, Chandra Bhagat Pharma's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Chandra Bhagat Pharma Gross Margin % vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Chandra Bhagat Pharma's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Chandra Bhagat Pharma's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Chandra Bhagat Pharma (BOM:542934) has a Gross Margin % of 16.64% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Chandra Bhagat Pharma and its competitors. This is 17% above median its historical median of 14.23. Over the past decade, Chandra Bhagat Pharma's Gross Margin % has ranged from 5.97 to 19.53. According to the industry distribution chart, Chandra Bhagat Pharma ranks #50 out of 116 companies in the Medical Distribution industry, placing it in the top 43.1%.
Is Chandra Bhagat Pharma's Gross Margin % too high?
Chandra Bhagat Pharma's current Gross Margin % of 16.64% is 17% above median its 10-year median of 14.23. Over the past 10 years, this metric has ranged from a low of 5.97 to a high of 19.53. The Medical Distribution industry median Gross Margin % is 14.90. Chandra Bhagat Pharma's value of 16.64% is 11.7% above this industry median. Based on the distribution chart, Chandra Bhagat Pharma ranks #50 out of 116 companies in the Medical Distribution industry, which is above the industry midpoint. Overall, Chandra Bhagat Pharma has a GF Score™ of 65/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Chandra Bhagat Pharma's Gross Margin % compare to MCK and CAH?
According to the Medical Distribution industry distribution chart, Chandra Bhagat Pharma ranks #50 out of 116 companies for Gross Margin %. This puts Chandra Bhagat Pharma in the upper half of its industry. The industry median Gross Margin % is 14.90. Chandra Bhagat Pharma's value of 16.64% is 11.7% above this benchmark. Historically, Chandra Bhagat Pharma's own Gross Margin % has ranged from 5.97 to 19.53 over the past decade. While the company's 10-year median is 14.23 vs. the industry median of 14.90, Chandra Bhagat Pharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Medical Distribution company?
The median Gross Margin % among Medical Distribution companies is 14.90, based on 116 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Chandra Bhagat Pharma's current Gross Margin % of 16.64% is 11.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Chandra Bhagat Pharma and its competitors. For the Medical Distribution industry, the median Gross Margin % is 14.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Chandra Bhagat Pharma's current Gross Margin % is 16.64%, which is 17% above median its own 10-year median of 14.23. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chandra Bhagat Pharma stock overvalued right now?
Based on GuruFocus' analysis, Chandra Bhagat Pharma (BOM:542934) is currently considered Possible Value Trap. The stock's GF Value™ is ₹70.19, compared to a current price of ₹34.79 — trading 50.4% below its estimated fair value. The current Gross Margin % is 16.64%, which is 17% above median its 10-year median of 14.23 and 11.7% above the Medical Distribution industry median of 14.90. Chandra Bhagat Pharma's overall GF Score™ is 65/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Chandra Bhagat Pharma (BOM:542934), the current Gross Margin % is 16.64% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Chandra Bhagat Pharma (BOM:542934) Overvalued in 2026?
Based on GuruFocus' analysis, Chandra Bhagat Pharma stock appears to be undervalued.
The current stock price of ₹34.79 is trading 50.4% below its estimated GF Value™ of ₹70.19.
GuruFocus considers Chandra Bhagat Pharma to be Possible Value Trap.
Key valuation signals for BOM:542934:
Gross Margin %: 16.64% (17% above median its 10-year median of 14.23)
GF Value™: ₹70.19 vs. price of ₹34.79 (50.4% below fair value)
Industry Position: 11.7% above the Medical Distribution median (#50 of 116)
No single metric tells the full story. See the BOM:542934 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Chandra Bhagat Pharma Ltd is a pharmaceutical company marketing pharmaceutical, critical care, and health care products across the globe. The company deals in many categories of pharmaceutical products like anticancer, cardiovascular, anti-infective, etc. It offers various forms of pharmaceutical products, like oral solids. tablets, capsules, liquid orals, syrup suspension, injections, liquid, powder, etc. Additionally, the company is also engaged in promoting and marketing of Active Pharmaceutical Ingredients (API's) in India.
65GF Score
Get the complete analysis for BOM:542934
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:542934 has been successfully added to your 
